NCT05807776View on ClinicalTrials.gov

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Resectable Hepatocellular Carcinoma
Interventions
DRUG

Tislelizumab

Tislelizumab 200mg, iv, d1, Q3W

DRUG

Tislelizumab, Lenvatinib

"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05807776 - Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. | Biotech Hunter | Biotech Hunter